Skip to main content
Premium Trial:

Request an Annual Quote

FDA Licenses GVK's GOSTAR Database for Drug Repurposing Research

Premium

This week, GVK Biosciences said that the US Food and Drug Administration has licensed GOSTAR, a manually curated database of structure-activity relationship, pharmacokinetic, and toxicity data.

GOSTAR contains over 6.5 million manually curated compounds from over 2.5 million patents and 400,000 journals; and more than 18 million quantitative SAR points. It also includes a proprietary drug repurposing platform that pulls in data from other GVK Bio proprietary databases.

GVK Bio said that it will collaborate with the FDA on drug repositioning projects, the first of which will identify alternative therapeutic indications for compounds used to treat neglected and orphan diseases.

The firm will also work with the FDA to enhance GOSTAR's "repositioning and repurposing workflow, and make it available to the entire research community," according to Sreeni Devidas, GVK Bio's vice president of business development.

The financial details of the agreement were not disclosed.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.